Global Flow Cytometry Market - 2024-2031

Overview

The global flow cytometry market reached US$ 4.76 billion in 2023 and is expected to reach US$ 8.24 billion by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.

Flow cytometry is an advanced method to identify and quantify the physical and chemical traits of cells or particles suspended in a liquid medium. This technique enables the swift examination of individual cells as they move past a laser beam, where they are illuminated and evaluated based on their light scattering and fluorescence characteristics.

Flow cytometry is a laser-driven technique that identifies and measures different characteristics of cells or particles, such as size, granularity, and specific protein markers using fluorescent labeling. This method allows healthcare professionals to analyze blood, bone marrow, and other bodily fluids samples. It is especially valuable for diagnosing diseases like cancer and infections by detecting and characterizing various cell types.

Market Dynamics: Drivers

Rising incidence of chronic diseases and technological advancements

The demand for the global flow cytometry market is driven by multiple factors. One of the primary factors is the rising incidence of chronic diseases and technological advancements. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is significantly driving the demand for advanced diagnostic tools like flow cytometers. Early diagnosis is essential for enhancing patient outcomes in chronic diseases. Flow cytometry provides quick and accurate analysis of cellular characteristics, allowing healthcare professionals to detect abnormalities at earlier stages.

Furthermore, continuous technological advancements in flow cytometry technology, particularly the emergence of high-throughput flow cytometry (HTFC) and spectral flow cytometry, are greatly improving data resolution and facilitating more intricate analyses. HTFC enables the examination of thousands of cells per second, which is vital for extensive research efforts. For instance, systems like HyperCyt allow for swift sample loading from multi-well plates, processing up to 40 wells every minute. This rapid throughput is essential in drug discovery and screening processes, where analyzing large quantities of samples quickly is crucial.

In addition, key players in the industry product launches and approvals that would drive this market growth. For instance, in May 2024, Agilent Technologies Inc. unveiled the NovoCyte Opteon Spectral Flow Cytometer, marking a significant advancement in flow cytometry accessibility. This innovative system establishes a new benchmark for acquiring, analyzing, and reporting flow data across various fields, including basic research, drug discovery, and therapy development.

Also, in January 2024, IDEX Health & Science launched the Semrock line of Nanopede Optical Filters, specifically designed for flow cytometry applications. The Nanopede filters are engineered to provide high transmission rates while effectively blocking unwanted light (optical density OD5) across the spectrum. This ensures that the fluorescence signals collected during flow cytometry are clear and accurate.

Similarly, in November 2023, CD Bioparticles announced the launch of a new range of Flow Cytometry Particles, which includes various types of polystyrene particles specifically designed for calibration and standardization in flow cytometry experiments.

Restraints

Factors such as high equipment costs, and lack of awareness among individuals, are expected to hamper the market.

Segment Analysis

The global flow cytometry market is segmented based on product type, technology, application, end-user, and region.

The reagents and consumables segment accounted for approximately 43.9% of the global flow cytometry market share

The reagents and consumables segment is expected to hold the largest market share over the forecast period. The reagents and consumables segment is a crucial element of the flow cytometry market, significantly contributing to its growth and application across multiple domains. This segment includes a variety of essential products for performing flow cytometry assays, such as antibodies, assays, kits, and various other reagents.

Moreover, key players in the industry have innovative product launches & approvals and technological advancements that would drive this market growth. For instance, in August 2024, Bio-Rad Laboratories, Inc. announced the launch of annexin V conjugated to eight StarBright Dyes: SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. These new Annexin V StarBright conjugates facilitate the detection of early apoptotic cells through flow cytometry and provide researchers with a broader selection of fluorophore options. This expansion enhances the ability to incorporate apoptosis detection into multicolor immunophenotyping panels for both conventional and full-spectrum flow cytometry applications.

Also, in May 2023, Sysmex Corporation launched its Clinical Flow Cytometry System, which includes the Flow Cytometer XF-1600 and Sample Preparation System PS-10, along with antibody reagents and related products in Japan. The introduction of the XF-1600 is anticipated to greatly enhance workflow efficiency in clinical laboratories by minimizing manual tasks and promoting standardization. This development aligns with Sysmex's dedication to improving diagnostic capabilities and tackling medical challenges through innovative solutions.

Similarly, in March 2024, Beckman Coulter Life Sciences received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its DxFLEX Clinical Flow Cytometer in the United States. This development brings the widely used benchtop IVD flow cytometry system to American laboratories while enhancing their testing capabilities. The DxFLEX system supports up to 13 colors, and additional detectors can be activated as laboratory needs change, eliminating the necessity for new hardware purchases.

Geographical Analysis

North America accounted for approximately 44.8% of the global flow cytometry market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of chronic diseases, especially cancer and immunodeficiency disorders, which is a significant factor driving the flow cytometry market. The American Cancer Society indicated that around 1.9 million new cancer cases would be diagnosed in the U.S. in 2022, which would drive the need for effective diagnostic tools like flow cytometry. As healthcare professionals increasingly seek faster and more precise diagnostic methods, the importance of flow cytometry continues to rise.

Technological advancements in flow cytometry are significantly enhancing its capabilities, leading to better resolution and sensitivity in quantifying different cell types. Innovations like multi-parameter analysis enable thorough immunophenotyping, which is vital for diagnosing and tracking diseases such as leukemia and lymphoma. Additionally, the launch of new instruments and software solutions is further driving market growth.

Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and government initiatives & regulatory support, and investment in research and development would drive this market growth. For instance, in June 2023, in New Jersey, BD (Becton, Dickinson and Company) announced the global launch of a new automated instrument designed for preparing samples for clinical diagnostics using flow cytometry. This innovative system facilitates a complete "walkaway" workflow solution aimed at enhancing standardization and reproducibility in cellular diagnostics.

Also, in May 2023, in New Jersey BD (Becton, Dickinson and Company) announced the global launch of an innovative cell sorting instrument that incorporates two innovative technologies, significantly enhancing the capabilities of flow cytometry.

Market Segmentation

By Product Type

• Reagents and Consumables
  • Antibodies
  • Assays and kits
  • Others
• Instruments
  • Cell Analyzers
  • Cell Sorters
• Software
• Accessories
• Services

By Technology

• Cell-Based
• Bead-Based

By Application

• Research
  • Drug Discovery
  • Stem Cell Research
  • Immunology Studies
  • Apoptosis Analysis
  • Cell Sorting and Viability Assessments
• Clinical
  • Cancer Detection
  • Organ Transplantation
  • Immunodeficiency Disorders
  • Hematology
• Industrial

By End-User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Clinical Testing Laboratories
• Blood Banks
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the flow cytometry market include Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec, Sysmex Corporation, bioMerieux, Cytek Biosciences, and Apogee Flow Systems Ltd. among others.

Key Developments

• In April 2024, Beckman Coulter Life Sciences introduced the QbD1200+ Total Organic Carbon (TOC) Analyzer. This new instrument simplifies and accelerates the analysis of pharmaceuticals and biopharmaceuticals, providing more robust data. It features streamlined validation processes and encrypted data reporting, ensuring compliance with 21 CFR Part 11 regulations and major global pharmacopeia standards.
• In March 2024, Beckman Coulter Life Sciences announced the launch of the CytoFLEX nano Flow Cytometer, a specialized instrument designed for research purposes that significantly enhances the capabilities of flow cytometry. It can detect particles as small as 40 nm, marking a significant improvement over traditional flow cytometers, which typically have higher detection thresholds. This enhanced capability allows researchers to analyze smaller biological entities, such as extracellular vesicles (EVs), that are crucial for understanding various biological processes and diseases.
• In January 2024, Cytek Biosciences, Inc. agreed with the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF). This collaboration aims to foster technological innovation and expedite discoveries for the scientific community.
• In January 2023, METAFORA Biosystems announced the launch of METAflow, its digital flow cytometry platform, into the Research Use Only (RUO) market. METAflow features a sophisticated suite of unsupervised algorithms that streamline the analysis process, making it accessible to users of all skill levels, from novices to experts. This cloud-based software automates the multidimensional clustering of flow cytometry data, representing a significant improvement over existing solutions that may not be as effective, regardless of the user's data processing abilities.

Why Purchase the Report?

• To visualize the global flow cytometry market segmentation based on product type, technology, application, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the flow cytometry market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global flow cytometry market report would provide approximately 70 tables, 65 figures, and 184 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies